Cargando…

Probabilistic forecasts of COVID-19 deaths with the progression rate from pneumonia to ARDS: An open-data-based global study

BACKGROUND: Cumulative data of case-fatality rates (CFR) of COVID-19 varied across countries. A forecasting model generated based on detailed information from three countries during the initial phase of pandemic showed that progression rates from pneumonia to ARDS (PRPA) varied by country and were h...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Wei-Jung, Chen, Yee-Chun, Hsu, Chen-Yang, Chen, Chih-Dao, Li-Sheng Chen, Sam, Chang, King-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Formosan Medical Association. Published by Elsevier Taiwan LLC. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165092/
https://www.ncbi.nlm.nih.gov/pubmed/34116895
http://dx.doi.org/10.1016/j.jfma.2021.05.016
_version_ 1783701240403722240
author Chang, Wei-Jung
Chen, Yee-Chun
Hsu, Chen-Yang
Chen, Chih-Dao
Li-Sheng Chen, Sam
Chang, King-Jen
author_facet Chang, Wei-Jung
Chen, Yee-Chun
Hsu, Chen-Yang
Chen, Chih-Dao
Li-Sheng Chen, Sam
Chang, King-Jen
author_sort Chang, Wei-Jung
collection PubMed
description BACKGROUND: Cumulative data of case-fatality rates (CFR) of COVID-19 varied across countries. A forecasting model generated based on detailed information from three countries during the initial phase of pandemic showed that progression rates from pneumonia to ARDS (PRPA) varied by country and were highly associated with CFR. We aim to elucidate the impact of the PRPA on COVID-19 deaths in different periods of pandemic. METHODS: We used the country-based, real-time global COVID-19 data through GitHub repository to estimate PRPA on the first period (January to June), second period (July to September), and third period (October to December) in 2020. PRPA was used for predicting COVID-19 deaths and assessing the reduction in deaths in subsequent two periods. RESULTS: The estimated PRPA varied widely from 0.38% to 51.36%, with an average of 15.99% in the first period. The PRPA declined to 8.44% and 6.35% in the second and third period. The CFR declined stepwise and was 4.94%, 2.61%, and 1.96%, respectively. Some countries exhibited a decrease in the PRPA from the second to the third period whereas others showed the opposite, particularly where selected viral mutants were prevalent. Overall, the number of observed deaths was lower than that of the predicted deaths in the second and third periods, suggesting an improvement in management of COVID-19 patients. Besides, the degree of improvement depends on the extent of change in PRPA. CONCLUSION: PRPA is a useful indicator to facilitate decision making and assess the improvement of clinical management and medical capacity by forecasting deaths.
format Online
Article
Text
id pubmed-8165092
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Formosan Medical Association. Published by Elsevier Taiwan LLC.
record_format MEDLINE/PubMed
spelling pubmed-81650922021-06-01 Probabilistic forecasts of COVID-19 deaths with the progression rate from pneumonia to ARDS: An open-data-based global study Chang, Wei-Jung Chen, Yee-Chun Hsu, Chen-Yang Chen, Chih-Dao Li-Sheng Chen, Sam Chang, King-Jen J Formos Med Assoc Original Article BACKGROUND: Cumulative data of case-fatality rates (CFR) of COVID-19 varied across countries. A forecasting model generated based on detailed information from three countries during the initial phase of pandemic showed that progression rates from pneumonia to ARDS (PRPA) varied by country and were highly associated with CFR. We aim to elucidate the impact of the PRPA on COVID-19 deaths in different periods of pandemic. METHODS: We used the country-based, real-time global COVID-19 data through GitHub repository to estimate PRPA on the first period (January to June), second period (July to September), and third period (October to December) in 2020. PRPA was used for predicting COVID-19 deaths and assessing the reduction in deaths in subsequent two periods. RESULTS: The estimated PRPA varied widely from 0.38% to 51.36%, with an average of 15.99% in the first period. The PRPA declined to 8.44% and 6.35% in the second and third period. The CFR declined stepwise and was 4.94%, 2.61%, and 1.96%, respectively. Some countries exhibited a decrease in the PRPA from the second to the third period whereas others showed the opposite, particularly where selected viral mutants were prevalent. Overall, the number of observed deaths was lower than that of the predicted deaths in the second and third periods, suggesting an improvement in management of COVID-19 patients. Besides, the degree of improvement depends on the extent of change in PRPA. CONCLUSION: PRPA is a useful indicator to facilitate decision making and assess the improvement of clinical management and medical capacity by forecasting deaths. Formosan Medical Association. Published by Elsevier Taiwan LLC. 2021-06 2021-05-31 /pmc/articles/PMC8165092/ /pubmed/34116895 http://dx.doi.org/10.1016/j.jfma.2021.05.016 Text en © 2021 Formosan Medical Association. Published by Elsevier Taiwan LLC. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Chang, Wei-Jung
Chen, Yee-Chun
Hsu, Chen-Yang
Chen, Chih-Dao
Li-Sheng Chen, Sam
Chang, King-Jen
Probabilistic forecasts of COVID-19 deaths with the progression rate from pneumonia to ARDS: An open-data-based global study
title Probabilistic forecasts of COVID-19 deaths with the progression rate from pneumonia to ARDS: An open-data-based global study
title_full Probabilistic forecasts of COVID-19 deaths with the progression rate from pneumonia to ARDS: An open-data-based global study
title_fullStr Probabilistic forecasts of COVID-19 deaths with the progression rate from pneumonia to ARDS: An open-data-based global study
title_full_unstemmed Probabilistic forecasts of COVID-19 deaths with the progression rate from pneumonia to ARDS: An open-data-based global study
title_short Probabilistic forecasts of COVID-19 deaths with the progression rate from pneumonia to ARDS: An open-data-based global study
title_sort probabilistic forecasts of covid-19 deaths with the progression rate from pneumonia to ards: an open-data-based global study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165092/
https://www.ncbi.nlm.nih.gov/pubmed/34116895
http://dx.doi.org/10.1016/j.jfma.2021.05.016
work_keys_str_mv AT changweijung probabilisticforecastsofcovid19deathswiththeprogressionratefrompneumoniatoardsanopendatabasedglobalstudy
AT chenyeechun probabilisticforecastsofcovid19deathswiththeprogressionratefrompneumoniatoardsanopendatabasedglobalstudy
AT hsuchenyang probabilisticforecastsofcovid19deathswiththeprogressionratefrompneumoniatoardsanopendatabasedglobalstudy
AT chenchihdao probabilisticforecastsofcovid19deathswiththeprogressionratefrompneumoniatoardsanopendatabasedglobalstudy
AT lishengchensam probabilisticforecastsofcovid19deathswiththeprogressionratefrompneumoniatoardsanopendatabasedglobalstudy
AT changkingjen probabilisticforecastsofcovid19deathswiththeprogressionratefrompneumoniatoardsanopendatabasedglobalstudy